Chelsea Therapeutics International has reported positive preliminary results from a Phase III trial evaluating Northera (droxidopa) in Parkinson’s disease patients with symptomatic neurogenic orthostatic hypotension (NOH).

Northera demonstrated statistically significant improvement over placebo in reduction of dizziness and lightheadedness at week one (p=0.018), the primary endpoint, and standing blood pressure at week one (p=0.032), a key secondary endpoint in study 306B.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

University of South Florida Parkinson’s Disease Movement Disorders Center director, professor of neurology, molecular pharmacology and physiology and study principal investigator Dr Robert Hauser said the current data is consistent with prior studies.

"Northera demonstrated statistically significant improvement over placebo in reduction of dizziness and lightheadedness at week one, the primary endpoint, and standing blood pressure at week one, a key secondary endpoint."

"They demonstrate an improvement in dizziness and lightheadedness and suggest a reduction in falls for patients taking Northera. In addition, Northera was well tolerated, with a relatively low incidence of supine hypertension," Hauser said.

Treatment with Northera resulted in fewer patient falls and fall-related injuries, although these results were not statistically significant.

See Also:

Preliminary safety data showed that Northera was well-tolerated at all tested dosages, and demonsted consistent safety results with those from previous studies.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Chelsea interim CEO Joseph Oliveto said the 306B results are consistent with the safety and efficacy of Northera observed in the previous randomiszed, controlled trials.

"Furthermore, we now have studied over 650 NOH patients, constituting a large safety and efficacy database in this orphan indication," Oliveto said.

The FDA had earlier advised Chelsea that study 306B is unlikely to provide sufficient confirmatory evidence to support a new drug application for Northera.